5Q Spectra to Present Promising Prostate Cancer Blood Test at Davos Healthcare

Major Advances in Prostate Cancer Detection: 5Q Spectra's New Study

In a significant development for urologic oncology, 5Q Spectra is set to unveil the next pivotal stage of its clinical program for the PSB blood test at the upcoming Davos Healthcare event on September 14, 2026. This breakthrough comes after over 15 years of rigorous scientific research aimed at establishing a new standard in prostate cancer detection.

The PSB blood test represents a major leap forward from traditional screening methods, which only provide binary positive or negative results. Instead, this innovative test offers a nuanced, quantitative score that evaluates various levels of prostate cancer risk, empowering urologists and their patients with more comprehensive information regarding elevated PSA levels. With this enhanced understanding, the decision-making process regarding further tests or interventions becomes significantly clearer.

The clinical program will commence with a retrospective study involving over 250 men diagnosed with prostate cancer, which aims to analyze previous data and understand the effectiveness of the PSB test in various circumstances. Following this, in early 2027, a substantial prospective randomized clinical trial is expected to enroll more than 1,000 patients, ensuring that the test's efficacy is validated across a broad and diverse population. This extensive research framework is designed to meet the rising demand for robust clinical evidence among physicians, health insurers, and health systems keen on adopting new diagnostic standards.

Dr. Rajiv Dahiya, Co-Founder and Managing Director of 5Q Spectra, emphasized the importance of clinical evidence in the adoption of breakthrough medical technologies, stating, "Real-world evidence and prospective validation are how we have built, and will continue to build, clinical confidence in 5Q's PSB blood test." He further remarked on the ultimate goal: to offer physicians and patients actionable insights into prostate cancer risk, leading to improved outcomes.

5Q's initiative marks a transformative moment in prostate cancer treatment pathways, highlighted by CEO Steven de Jaray. He expressed excitement for this pivotal phase, noting, "After fifteen years of new science and development, we are expanding the medical and clinical foundation needed to take PSB from our current patient introduction toward everyday prostate cancer care around the world."

Not only does the PSB blood test enhance current diagnostic capabilities, but it also has the potential to reshape the standard of care for managing elevated PSA readings, providing healthcare professionals with a powerful tool for patient treatment strategies.

Founded with the mission to develop impactful diagnostic solutions, 5Q Spectra is committed to advancing treatment options in cancer care. Its flagship product, Prostate Dx™ / PSB test, is currently available as a Laboratory Developed Test (LDT) through CLIA-certified laboratories, positioning the company at the forefront of next-generation molecular diagnostics.

As 5Q Spectra prepares to launch this important clinical study, anticipation builds among the medical community for the potential improvements to the standardized approach in detecting and managing prostate cancer. By championing advanced diagnostic techniques, 5Q aims to foster a new era in urologic oncology, ultimately helping more patients receive timely and effective care.